Core Insights - Mirion Technologies is expected to close with gains today, contrasting with the likely declines of the Dow Jones Industrial Average and S&P 500 [1] - As of 1:46 p.m. ET, shares of Mirion Technologies increased by 17.1% [2] Financial Performance - For Q3 2025, Mirion reported revenue of $223.1 million and adjusted earnings per share (EPS) of $0.12, surpassing analysts' expectations of $222.2 million in revenue and $0.10 in EPS [4] - The company's Q3 2025 revenue showed a year-over-year increase of 7.3%, while adjusted EPS reflected a 50% increase compared to the same period in 2024 [5] Future Guidance - Management reaffirmed its 2025 financial guidance, projecting revenue growth of 7% to 9% year-over-year and adjusted EBITDA between $223 million and $233 million, indicating a potential 12% year-over-year increase at the midpoint [6] Market Position - The acquisition of Paragon positions Mirion favorably within the small modular reactor (SMR) market, providing exposure without the associated risks of investing in SMR companies like NuScale Power and Oklo [7][9]

Core Insights - Mirion Technologies' shares surged 18.2% following a strong earnings report, driven by growth in its nuclear energy-related business [1] Financial Performance - In Q3, Mirion reported a revenue increase of 7.9% to $223.1 million and a 50% rise in non-GAAP earnings per share to $0.12, both exceeding expectations [2] - The company anticipates 7% to 9% growth for the year, with approximately 1 percentage point attributed to recent acquisitions in the nuclear segment [3] - Adjusted EPS is projected at $0.50 at the midpoint, with adjusted free cash flow expected between $100 million and $115 million, with the lower end of guidance raised since the last quarter [3] Segment Analysis - The nuclear segment is the larger and faster-growing part of Mirion's business, achieving 9% growth last quarter to $144.6 million, making up nearly two-thirds of total revenue, while the medical segment grew only 5.9% [4] - A 21% increase in the nuclear safety segment order book was reported, driven by a significant order from a small modular reactor customer, although the medical order book declined [5] Market Trends - The nuclear energy sector has seen substantial growth, with Mirion's stock up 70.3% for 2025, currently trading at over 70 times this year's adjusted free cash flow estimates [7] - Despite strong results, the stock is considered expensive, with expectations of mid-single-digit organic growth this year [9]

Financial Data and Key Metrics Changes - Third quarter revenue totaled $223 million, an increase of nearly 8% from the previous year, with organic revenue growth of 4.7% [7][20] - Adjusted EBITDA for the quarter was $52.4 million, up 14.7% year-over-year, with margin expansion contributing to the increase [8][21] - Adjusted free cash flow for the third quarter was $18 million, contributing to a year-to-date total of $53 million, leading to an increase in adjusted free cash flow guidance for 2025 to between $100 million and $115 million [8][25] - Adjusted EPS was $0.12 per share, a 50% increase compared to the same quarter last year [21] Business Line Data and Key Metrics Changes - The nuclear and safety segment revenue grew 9% to $144.6 million, with organic growth of 4.4% [23] - The medical segment revenue totaled $78.5 million, up 5.9%, with organic revenue growth of 5.2% [24] - Adjusted orders in the nuclear power end market grew 21%, reflecting strong demand across new builds, SMRs, and the installed base [10][16] Market Data and Key Metrics Changes - Year-to-date orders in the U.S. nuclear power end market increased by 44%, primarily driven by SMR activity [16] - The global nuclear fleet's average capacity factor reached 83% in 2024, indicating potential for increased operational efficiency [11] - The IAEA has raised its nuclear capacity forecast, expecting nearly a terawatt of nuclear capacity by 2050 [11] Company Strategy and Development Direction - The company is focused on broadening its nuclear power portfolio through acquisitions, including the recent Paragon Energy Solutions deal [6][14] - The strategy includes enhancing software solutions for regulatory compliance and expanding the U.S. presence with additional products and services [13][14] - The company aims to capitalize on the nuclear renaissance and is optimistic about the growth potential in the nuclear power sector [5][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the nuclear power market's growth, citing strong order flow and favorable trends in SMR orders [9][10] - The medical segment is expected to normalize despite current pressures, with continued demand driven by aging populations and increased cancer incidence [35][37] - Management remains optimistic about achieving a level of equilibrium in the U.S. healthcare environment, which has been impacted by budgetary constraints [71][72] Other Important Information - The company expects to maintain a blended cost of debt of 2.8% into 2026, reflecting a significant improvement over the past year [8] - The company has a robust opportunity pipeline, with $285 million still to be awarded, of which $175 million is expected to be awarded by year-end [19][42] Q&A Session Summary Question: Regarding the commercial nuclear backlog and potential acceleration - Management indicated that the installed base and new utility scale builds are key drivers for future backlog growth, with government support expected to streamline project timelines [31][32] Question: Insights on the medical business amidst current pressures - Management remains positive about the medical business, citing strong demand drivers and expecting normalization in the RTQA segment [35][37] Question: Confidence in the $175 million pipeline and potential awards - Management expressed confidence in the pipeline, noting that timing is unpredictable but they feel they have a strong right to win on these opportunities [42] Question: Discussion on SMR opportunities and related projects - Management highlighted the expanding SMR opportunity set, with over 120 projects in development and significant government support aiding market evolution [46][62] Question: Pricing power trends in nuclear safety versus medical - Management noted that pricing power remains strong, particularly in the nuclear segment, while being more cautious in the medical segment due to current market conditions [68] Question: U.S. healthcare environment impacts on business - Management explained that Medicaid cuts and overall market noise have created a defensive CapEx environment, but they expect demand dynamics to normalize [71][72]

Financial Data and Key Metrics Changes - Third quarter revenue totaled $223 million, an increase of nearly 8% from the previous year, with organic revenue growth of 4.7% [6][19] - Adjusted EBITDA for the quarter was $52.4 million, up 14.7% year-over-year, with margin expansion contributing to the increase [7][20] - Adjusted free cash flow for the third quarter was $18 million, contributing to a year-to-date total of $53 million, leading to an increase in adjusted free cash flow guidance for 2025 to between $100 million and $115 million [7][24] - Adjusted EPS was $0.12 per share, a 50% increase compared to the same quarter last year [20] Business Line Data and Key Metrics Changes - Nuclear and safety segment revenue grew 9% to $144.6 million, with organic growth of 4.4% [22] - Medical segment revenue totaled $78.5 million, up 5.9%, with organic revenue growth of 5.2% [23] - Adjusted orders in the nuclear power end market grew 21%, reflecting strong demand across new builds, SMRs, and the installed base [9][15] Market Data and Key Metrics Changes - Year-to-date orders in the U.S. nuclear power end market increased by 44%, primarily driven by SMR activity [15] - The global nuclear fleet's average capacity factor reached 83% in 2024, indicating a positive trend for nuclear power utilization [10] - The IAEA has increased its nuclear capacity forecast, expecting nearly a terawatt of nuclear capacity by 2050 [10] Company Strategy and Development Direction - The company is focused on expanding its nuclear power portfolio through acquisitions, including the recent Paragon Energy Solutions deal [5][12] - The strategy includes enhancing software solutions for regulatory compliance and broadening product offerings in the nuclear power sector [12][13] - The company remains optimistic about the nuclear renaissance and its positioning to benefit from it [5][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the nuclear power market's growth, citing strong order flow and government support for new projects [31][32] - The medical segment is expected to normalize despite current pressures, with continued demand for cancer care solutions [36][71] - Management anticipates a rebound in the RTQA business as funding dynamics stabilize [36] Other Important Information - The company expects to close the Paragon acquisition by year-end, which will enhance its U.S. presence and product offerings [5][12] - The company is actively managing supply chain risks and has developed strategies to mitigate exposure to critical commodities [65][66] Q&A Session Summary Question: Regarding the commercial nuclear backlog and project activity - Management indicated that the installed base and new utility scale builds are key drivers for future backlog growth, with government support expected to streamline project timelines [30][31] Question: Insights on the medical business amidst current pressures - Management remains optimistic about the medical segment, citing strong demand drivers and expecting normalization in the RTQA business [34][36] Question: Confidence in the $175 million pipeline and potential awards - Management expressed confidence in the pipeline, noting that timing for large opportunities can be unpredictable but remains optimistic about winning a significant portion [41] Question: Clarification on SMR opportunities and project details - Management highlighted the expanding SMR project pipeline and the importance of government support in accelerating market growth [44][61] Question: Pricing power trends in nuclear safety versus medical - Management noted positive pricing dynamics in the nuclear segment, while being more cautious in the medical segment due to current market conditions [68] Question: Impact of U.S. healthcare environment on business - Management discussed the effects of Medicaid cuts and overall market noise on capital expenditures, but remains confident in the underlying demand for their solutions [71]

Financial Data and Key Metrics Changes - Third quarter revenue totaled $223 million, an increase of nearly 8% from the previous year, with organic revenue growth of 4.7% [5][17] - Adjusted EBITDA for the quarter was $52.4 million, up 14.7% year-over-year, with margin expansion contributing to the increase [6][18] - Adjusted free cash flow for the third quarter was $18 million, contributing to a year-to-date total of $53 million, with an increase in the low end of adjusted free cash flow guidance to between $100 million and $115 million for 2025 [6][22] Business Line Data and Key Metrics Changes - The nuclear and safety segment revenue grew 9% to $144.6 million, with organic growth of 4.4% driven by nuclear power end market growth of 9% [20] - The medical segment revenue totaled $78.5 million, up 5.9%, with organic revenue growth of 5.2% [21] - Adjusted orders in the nuclear power end market grew 21%, reflecting strong demand across new builds, SMRs, and the installed base [8][14] Market Data and Key Metrics Changes - Year-to-date orders in the U.S. nuclear power end market increased by 44%, primarily due to SMR activity [14] - The global nuclear fleet's average capacity factor reached 83% in 2024, indicating potential for increased operational efficiency [9] - The IAEA has raised its nuclear capacity forecast, expecting nearly a terawatt of nuclear capacity by 2050 [9] Company Strategy and Development Direction - The company is focused on broadening its nuclear power portfolio through acquisitions, including the recent Paragon Energy Solutions deal [5][11] - The strategy includes enhancing software solutions for regulatory compliance and expanding product offerings in the nuclear power sector [11] - The company remains optimistic about the nuclear renaissance and its positioning to benefit from it [5][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the nuclear power market's growth, citing strong order flow and government support for new projects [28][30] - The medical segment is expected to normalize despite current pressures, with continued demand driven by demographic trends and cancer care needs [31][32] - Management anticipates a rebound in the RTQA business as funding dynamics stabilize [32] Other Important Information - The company expects a blended cost of debt of 2.8% by year-end 2025, reflecting a significant improvement over the past year [6] - Adjusted EPS for the third quarter was $0.12, a 50% increase compared to the same quarter last year [18] Q&A Session Summary Question: Regarding the commercial nuclear backlog and project activity - Management indicated that the installed base and new utility scale builds are key drivers for future growth, with expectations for a growing nuclear power-related backlog [25][27] Question: Insights on the medical business amidst current pressures - Management remains optimistic about the medical business, citing strong demand drivers and expecting a return to trend as market conditions normalize [31][32] Question: Confidence in the $175 million pipeline and potential awards - Management expressed confidence in the pipeline, noting that timing for large opportunities can be unpredictable but remains optimistic about winning contracts [36][37] Question: Discussion on SMR opportunities and project pipeline - Management highlighted the expanding SMR project landscape and the importance of government support in accelerating project development [39][54] Question: Impact of larger one-time orders on margin profiles - Management confirmed a commitment to maintaining a 30% adjusted EBITDA margin target, with expectations that new builds may have lower margins compared to installed base work [71]

Q3 2025 Performance - Revenue reached $223.1 million, with organic growth of 4.7% compared to Q3 2024[12] - Adjusted EBITDA increased by 14.7% to $52.4 million compared to Q3 2024, with contributions from both segments[15] - Adjusted Free Cash Flow generation was $18 million in Q3 2025, with $53 million YTD and a 35% YTD conversion rate[12] - Adjusted diluted EPS increased by 50% to $0.12[41] Nuclear Power Momentum - Nuclear Power end-market organic revenue grew by 11% YTD[8] - Adjusted Orders in Nuclear Power end-market increased by 21% in Q3 2025 compared to Q3 2024[16] - SMR-related orders amounted to $17 million in Q3 2025, a 9% increase compared to Q3 2024[17] - A $10 million SMR new build order was secured in Q3 2025, and a $55 million installed base order was secured in October 2025[8] Medical Segment Update - Approximately 75% of the Medical segment's revenue is directly related to cancer care[27] - Dosimetry organic revenue grew by 7%[57] 2025 Guidance - The company is on track for 2025 guidance[11] - Organic Revenue Growth is projected between 4.5% and 6.0%, and Total Revenue Growth between 7.0% and 9.0%[62]

Core Insights - Mirion Technologies, Inc. reported quarterly earnings of $0.12 per share, exceeding the Zacks Consensus Estimate of $0.11 per share, and showing an increase from $0.08 per share a year ago, resulting in an earnings surprise of +9.09% [1] - The company posted revenues of $223.1 million for the quarter ended September 2025, slightly missing the Zacks Consensus Estimate by 0.07%, but up from $206.8 million year-over-year [2] - Mirion Technologies shares have increased approximately 40.6% since the beginning of the year, outperforming the S&P 500's gain of 16.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.17 on revenues of $273.88 million, and for the current fiscal year, it is $0.48 on revenues of $922 million [7] - The estimate revisions trend for Mirion Technologies was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Technology Services industry, to which Mirion Technologies belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Financial Performance - Revenue for Q3 2025 increased by 7.9% to $223.1 million, compared to $206.8 million in Q3 2024[5] - GAAP net income for Q3 2025 was $3.1 million, a 122% improvement from a GAAP net loss of $14.0 million in Q3 2024[5] - Adjusted EBITDA for Q3 2025 was $52.4 million, a 14.7% increase from $45.7 million in Q3 2024[5] - Adjusted EPS for Q3 2025 was $0.12, compared to $0.08 in Q3 2024[5] - Total revenues for the three months ended September 30, 2025, were $223.1 million, a 7.5% increase from $206.8 million in the same period of 2024[21] - Net income attributable to Mirion Technologies, Inc. for the three months ended September 30, 2025, was $2.9 million, a significant improvement from a net loss of $13.6 million in the same period of 2024[21] - The net income attributable to Mirion Technologies for the three months ended September 30, 2025, was $2.9 million, compared to a loss of $13.6 million in the same period of 2024, indicating a significant turnaround in profitability[38] - Adjusted net income for the same period was $31.4 million, up from $17.4 million year-over-year, showcasing strong operational performance[38] - The company reported a GAAP earnings per share of $0.01 for the three months ended September 30, 2025, compared to a loss of $0.07 per share in the prior year[38] - Adjusted earnings per share increased to $0.12 from $0.08, reflecting improved profitability and operational efficiency[38] Revenue Guidance and Expectations - The company expects total revenue growth of approximately 7.0% – 9.0% for 2025, including a foreign exchange rate tailwind of approximately 180 basis points[6] - The company reaffirmed its 2025 guidance for total revenue growth, organic revenue growth, adjusted EBITDA, and adjusted EPS[5] Cash Flow and Financial Position - Adjusted Free Cash Flow is projected to be approximately $100 million – $115 million for 2025, with a conversion rate of approximately 45% – 49% of Adjusted EBITDA[11] - Cash and cash equivalents increased to $933.6 million as of September 30, 2025, up from $175.6 million at the beginning of the period[23] - Total assets reached $3,495.8 million as of September 30, 2025, compared to $2,636.0 million at December 31, 2024, marking a 32.6% increase[19] - Total liabilities increased to $1,603.8 million as of September 30, 2025, compared to $1,076.9 million at December 31, 2024[19] - Operating cash flow for the nine months ended September 30, 2025, was $70.3 million, compared to $38.3 million for the same period in 2024[23] Acquisitions and Business Development - Mirion announced an agreement to acquire Paragon Energy Solutions to enhance its U.S. nuclear power presence, expected to increase nuclear power-based revenue to approximately 45% of total revenue[3] - The company was awarded a $10 million order for small modular reactor new builds and a $55 million order for the Asia installed base in Q3 2025[4] - There remains a $285 million large opportunity pipeline, with $175 million of orders expected to be awarded in 2025 and $110 million in 2026[4] - The company completed acquisitions totaling $79.9 million during the nine months ended September 30, 2025[23] Operational Efficiency - For the three months ended September 30, 2025, Mirion Technologies reported an Adjusted EBITDA of $52.4 million, an increase from $45.7 million in the same period of 2024, reflecting a margin improvement from 22.1% to 23.5%[37] - The income from operations margin improved to 3.3% in Q3 2025, compared to a negative margin of 0.8% in Q3 2024, indicating better cost management[37] - Non-operating expenses for the three months ended September 30, 2025, were reported at $5.4 million, up from $4.1 million in the same period of 2024, highlighting ongoing restructuring and operational synergy costs[37] Research and Development - Research and development expenses for the nine months ended September 30, 2025, were $28.8 million, compared to $26.9 million for the same period in 2024[21] Shareholder Information - The company reported a total of 244,370,206 shares of Class A common stock outstanding as of September 30, 2025[24] - The weighted average common shares outstanding increased to 224.583 million in Q3 2025 from 206.676 million in Q3 2024, impacting per-share metrics[38] Non-GAAP Measures - The company emphasized the importance of non-GAAP measures for evaluating ongoing operations, with organic revenue defined as revenue excluding the impact of foreign exchange and M&A activities[26] - Adjusted free cash flow conversion was defined as adjusted free cash flow divided by adjusted EBITDA, providing insights into cash generation capabilities for future investments[32]

Core Insights - Mirion reported strong financial performance in Q3 2025, driven by growth in the nuclear power sector, aligning with its 2025 guidance [2][4] - The company announced the acquisition of Paragon Energy Solutions to enhance its nuclear power offerings, which is expected to increase nuclear revenue to approximately 45% of total revenue [2][3] - Mirion has a significant order pipeline, including a $10 million order for small modular reactors and a $55 million order for the Asia installed base, contributing to a total of $350 million in potential orders [3] Financial Performance - Revenue growth is projected at approximately 7.0% – 9.0%, with organic revenue growth expected to be around 4.5% – 6.0% [7] - Adjusted EBITDA is forecasted to be between $223 million and $233 million, with an adjusted EBITDA margin of approximately 24.0% – 25.0% [7] - Adjusted Free Cash Flow is anticipated to be between $100 million and $115 million, an increase from the previous range of $95 million – $115 million [7] Guidance and Future Outlook - The company raised the lower end of its adjusted Free Cash Flow guidance while reaffirming other financial metrics for 2025 [4] - Mirion plans to share its 2026 expectations in February 2026, indicating confidence in its operational strategy [4] - The guidance does not account for the impact of the Paragon acquisition, suggesting potential for further growth [5]

Core Insights - Conestoga Capital Advisors reported that equity markets reached new all-time highs in Q3 2025, but the Conestoga Small Cap Composite underperformed the Russell 2000 Growth Index, returning -1.4% compared to the Index's 12.2% gain [1] - The gains in the Russell 2000 Growth Index were primarily driven by low-quality stocks, particularly unprofitable, high-beta names [1] Company Highlights: Mirion Technologies, Inc. (NYSE:MIR) - Mirion Technologies, Inc. specializes in radiation detection, measurement, analysis, and monitoring products for medical and nuclear safety applications [2][3] - The stock of Mirion Technologies gained 1.30% over the past month and 71.94% over the last 52 weeks, closing at $24.17 with a market capitalization of $6.053 billion on October 17, 2025 [2] - The company benefits from durable demand drivers such as increased focus on nuclear energy, healthcare imaging, and global safety standards, generating recurring revenue through service contracts and consumables [3] Financial Performance - In Q2 2025, Mirion Technologies reported revenue of $222.9 million, reflecting a year-over-year increase of 7.6% [4] - The number of hedge funds holding Mirion Technologies increased from 35 to 46 in the second quarter of 2025, indicating growing interest among institutional investors [4] Investment Outlook - Mirion Technologies is viewed as having attractive growth potential due to improving margins, deleveraging progress, and exposure to long-term infrastructure and energy trends [3] - Despite the potential of Mirion Technologies, the company is not considered among the top 30 most popular stocks among hedge funds, and there are suggestions that certain AI stocks may offer greater upside potential with less downside risk [4]